Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

CYP17 inhibitors for prostate cancer treatment--an update.

Moreira VM, Salvador JA, Vasaitis TS, Njar VC.

Curr Med Chem. 2008;15(9):868-99. Review.

PMID:
18473796
2.
3.

CYP17 inhibitors for prostate cancer therapy.

Vasaitis TS, Bruno RD, Njar VC.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):23-31. doi: 10.1016/j.jsbmb.2010.11.005. Epub 2010 Nov 17. Review.

4.

17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.

Owen CP.

Anticancer Agents Med Chem. 2009 Jul;9(6):613-26. Review.

PMID:
19601745
5.

Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.

Leroux F.

Curr Med Chem. 2005;12(14):1623-9. Review.

PMID:
16022662
6.

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS.

Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Review.

PMID:
18619560
7.

Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.

Hu Q, Yin L, Jagusch C, Hille UE, Hartmann RW.

J Med Chem. 2010 Jul 8;53(13):5049-53. doi: 10.1021/jm100400a.

PMID:
20550118
8.

Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.

Salvador JA, Pinto RM, Silvestre SM.

J Steroid Biochem Mol Biol. 2013 Sep;137:199-222. doi: 10.1016/j.jsbmb.2013.04.006. Epub 2013 May 18. Review.

PMID:
23688836
9.
10.

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.

Rafferty SW, Eisner JR, Moore WR, Schotzinger RJ, Hoekstra WJ.

Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. doi: 10.1016/j.bmcl.2014.04.024. Epub 2014 Apr 16.

PMID:
24775307
11.

Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.

Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AM, Njar VC.

J Med Chem. 2003 Jun 5;46(12):2345-51.

PMID:
12773039
12.

P450-dependent enzymes as targets for prostate cancer therapy.

De Coster R, Wouters W, Bruynseels J.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):133-43. Review.

PMID:
8603034
13.

Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.

Hu Q, Jagusch C, Hille UE, Haupenthal J, Hartmann RW.

J Med Chem. 2010 Aug 12;53(15):5749-58. doi: 10.1021/jm100317b.

PMID:
20684610
14.

Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.

Hartmann RW, Ehmer PB, Haidar S, Hector M, Jose J, Klein CD, Seidel SB, Sergejew TF, Wachall BG, Wächter GA, Zhuang Y.

Arch Pharm (Weinheim). 2002 Apr;335(4):119-28. Review.

PMID:
12112031
15.

The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.

Hu Q, Negri M, Olgen S, Hartmann RW.

ChemMedChem. 2010 Jun 7;5(6):899-910. doi: 10.1002/cmdc.201000065.

PMID:
20437447
16.

CYP17A1: a biochemistry, chemistry, and clinical review.

Porubek D.

Curr Top Med Chem. 2013;13(12):1364-84. Review.

PMID:
23688130
17.
18.

CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Yin L, Hu Q.

Nat Rev Urol. 2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26. Review.

PMID:
24276076
19.

Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.

Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM.

Br J Cancer. 1999 Oct;81(4):622-30.

20.

Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.

Pinto-Bazurco Mendieta MA, Hu Q, Engel M, Hartmann RW.

J Med Chem. 2013 Aug 8;56(15):6101-7. doi: 10.1021/jm400484p. Epub 2013 Jul 29.

PMID:
23859149

Supplemental Content

Support Center